Ie-Ming Shih

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2914247/publications.pdf

Version: 2024-02-01

280 papers	34,512 citations	3149 92 h-index	3903 177 g-index
284 all docs	284 docs citations	284 times ranked	29996 citing authors

#	Article	IF	Citations
1	The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory. American Journal of Surgical Pathology, 2010, 34, 433-443.	2.1	1,503
2	ARID1AMutations in Endometriosis-Associated Ovarian Carcinomas. New England Journal of Medicine, 2010, 363, 1532-1543.	13.9	1,460
3	TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 6021-6026.	3.3	1,202
4	Ovarian Tumorigenesis. American Journal of Pathology, 2004, 164, 1511-1518.	1.9	1,107
5	Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma. Science, 2010, 330, 228-231.	6.0	1,090
6	Molecular pathogenesis and extraovarian origin of epithelial ovarian cancerâ€"Shifting the paradigm. Human Pathology, 2011, 42, 918-931.	1.1	932
7	Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer. Cell, 2016, 166, 755-765.	13.5	804
8	Mutations in BRAF and KRAS Characterize the Development of Low-Grade Ovarian Serous Carcinoma. Journal of the National Cancer Institute, 2003, 95, 484-486.	3.0	762
9	The Dualistic Model of Ovarian Carcinogenesis. American Journal of Pathology, 2016, 186, 733-747.	1.9	717
10	Ovarian Cancer. Annual Review of Pathology: Mechanisms of Disease, 2009, 4, 287-313.	9.6	576
11	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers. Clinical Chemistry, 2008, 54, e11-e79.	1.5	539
12	Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nature Medicine, 2015, 21, 231-238.	15.2	530
13	High grade serous ovarian carcinomas originate in the fallopian tube. Nature Communications, 2017, 8, 1093.	5.8	515
14	The role of chromosomal instability in tumor initiation. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 16226-16231.	3.3	484
15	Ovarian Low-grade and High-grade Serous Carcinoma. Advances in Anatomic Pathology, 2009, 16, 267-282.	2.4	477
16	Cancer-Associated Mutations in Endometriosis without Cancer. New England Journal of Medicine, 2017, 376, 1835-1848.	13.9	451
17	Prevalence of the Alternative Lengthening of Telomeres Telomere Maintenance Mechanism in Human Cancer Subtypes. American Journal of Pathology, 2011, 179, 1608-1615.	1.9	423
18	Frequent Activating Mutations of PIK3CA in Ovarian Clear Cell Carcinoma. American Journal of Pathology, 2009, 174, 1597-1601.	1.9	409

#	Article	IF	Citations
19	Are All Pelvic (Nonuterine) Serous Carcinomas of Tubal Origin?. American Journal of Surgical Pathology, 2010, 34, 1407-1416.	2.1	395
20	Notch Signaling, Î³-Secretase Inhibitors, and Cancer Therapy: Figure 1.. Cancer Research, 2007, 67, 1879-1882.	0.4	394
21	ARID1A, a Factor That Promotes Formation of SWI/SNF-Mediated Chromatin Remodeling, Is a Tumor Suppressor in Gynecologic Cancers. Cancer Research, 2011, 71, 6718-6727.	0.4	390
22	Patterns of p53 Mutations Separate Ovarian Serous Borderline Tumors and Low- and High-grade Carcinomas and Provide Support for a New Model of Ovarian Carcinogenesis. American Journal of Surgical Pathology, 2005, 29, 218-224.	2.1	388
23	Pathogenesis of Ovarian Cancer. International Journal of Gynecological Pathology, 2008, PAP, 151-60.	0.9	385
24	ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors. Cancer Discovery, 2015, 5, 752-767.	7.7	361
25	Epithelioid Trophoblastic Tumor. American Journal of Surgical Pathology, 1998, 22, 1393-1403.	2.1	336
26	TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic highâ€grade serous carcinomaâ€"evidence supporting the clonal relationship of the two lesions. Journal of Pathology, 2012, 226, 421-426.	2.1	332
27	Diverse Tumorigenic Pathways in Ovarian Serous Carcinoma. American Journal of Pathology, 2002, 160, 1223-1228.	1.9	320
28	MicroRNA Expression and Identification of Putative miRNA Targets in Ovarian Cancer. PLoS ONE, 2008, 3, e2436.	1.1	303
29	The Pathology of Intermediate Trophoblastic Tumors and Tumor-like Lesions. International Journal of Gynecological Pathology, 2001, 20, 31-47.	0.9	277
30	Evaluation of DNA from the Papanicolaou Test to Detect Ovarian and Endometrial Cancers. Science Translational Medicine, 2013, 5, 167ra4.	5.8	264
31	Notch3 Gene Amplification in Ovarian Cancer. Cancer Research, 2006, 66, 6312-6318.	0.4	257
32	Increased plasma DNA integrity in cancer patients. Cancer Research, 2003, 63, 3966-8.	0.4	252
33	Mutation and Loss of Expression of ARID1A in Uterine Low-grade Endometrioid Carcinoma. American Journal of Surgical Pathology, 2011, 35, 625-632.	2.1	251
34	Long Interspersed Element-1 Protein Expression Is a Hallmark of Many Human Cancers. American Journal of Pathology, 2014, 184, 1280-1286.	1.9	250
35	A Fluorescence Light-Up Ag Nanocluster Probe That Discriminates Single-Nucleotide Variants by Emission Color. Journal of the American Chemical Society, 2012, 134, 11550-11558.	6.6	238
36	Fallopian tube precursors of ovarian lowâ€•and highâ€grade serous neoplasms. Histopathology, 2013, 62, 44-58.	1.6	238

#	Article	IF	Citations
37	Identification of Molecular Pathway Aberrations in Uterine Serous Carcinoma by Genome-wide Analyses. Journal of the National Cancer Institute, 2012, 104, 1503-1513.	3.0	231
38	Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E10981-E10990.	3.3	217
39	The Origin and Pathogenesis of Endometriosis. Annual Review of Pathology: Mechanisms of Disease, 2020, 15, 71-95.	9.6	213
40	Proteomic Approaches to Tumor Marker Discovery. Archives of Pathology and Laboratory Medicine, 2002, 126, 1518-1526.	1.2	203
41	The emerging roles of ARID1A in tumor suppression. Cancer Biology and Therapy, 2014, 15, 655-664.	1.5	200
42	Principle and applications of digital PCR. Expert Review of Molecular Diagnostics, 2004, 4, 41-47.	1.5	189
43	Mutations of BRAF and KRAS Precede the Development of Ovarian Serous Borderline Tumors. Cancer Research, 2004, 64, 6915-6918.	0.4	186
44	Lowâ€grade serous carcinomas of the ovary contain very few point mutations. Journal of Pathology, 2012, 226, 413-420.	2.1	186
45	Gestational trophoblastic neoplasiaâ€”pathogenesis and potential therapeutic targets. Lancet Oncology, The, 2007, 8, 642-650.	5.1	183
46	Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. American Journal of Obstetrics and Gynecology, 2008, 198, 351-356.	0.7	178
47	Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. Science Translational Medicine, 2018, 10, .	5.8	178
48	Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 3089-3094.	3.3	175
49	Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma. Nature Communications, 2017, 8, 990.	5.8	169
50	Analysis of DNA Copy Number Alterations in Ovarian Serous Tumors Identifies New Molecular Genetic Changes in Low-Grade and High-Grade Carcinomas. Cancer Research, 2009, 69, 4036-4042.	0.4	166
51	Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biology and Therapy, 2006, 5, 779-785.	1.5	165
52	Utility of p16 Expression for Distinction of Uterine Serous Carcinomas From Endometrial Endometrioid and Endocervical Adenocarcinomas. American Journal of Surgical Pathology, 2009, 33, 1504-1514.	2.1	163
53	Notch3 Overexpression Is Related to the Recurrence of Ovarian Cancer and Confers Resistance to Carboplatin. American Journal of Pathology, 2010, 177, 1087-1094.	1.9	162
54	APC/CTNNB1 (?-catenin) pathway alterations in human prostate cancers. Genes Chromosomes and Cancer, 2002, 34, 9-16.	1.5	152

#	Article	IF	Citations
55	Diagnosis of Serous Tubal Intraepithelial Carcinoma Based on Morphologic and Immunohistochemical Features. American Journal of Surgical Pathology, 2011, 35, 1766-1775.	2.1	151
56	Loss of ARID1A Expression Is an Early Molecular Event in Tumor Progression From Ovarian Endometriotic Cyst to Clear Cell and Endometrioid Carcinoma. International Journal of Gynecological Cancer, 2012, 22, 1310-1315.	1.2	148
57	p63 Expression Is Useful in the Distinction of Epithelioid Trophoblastic and Placental Site Trophoblastic Tumors by Profiling Trophoblastic Subpopulations. American Journal of Surgical Pathology, 2004, 28, 1177-1183.	2.1	147
58	PD-L1 Expression in Human Placentas and Gestational Trophoblastic Diseases. International Journal of Gynecological Pathology, 2017, 36, 146-153.	0.9	145
59	Ki-67 labeling index in the differential diagnosis of exaggerated placental site, placental site trophoblastic tumor, and choriocarcinoma: A double immunohistochemical staining technique using Ki-67 and Mel-CAM antibodies. Human Pathology, 1998, 29, 27-33.	1.1	143
60	Functional Genomic Analysis Identified Epidermal Growth Factor Receptor Activation as the Most Common Genetic Event in Oral Squamous Cell Carcinoma. Cancer Research, 2009, 69, 2568-2576.	0.4	143
61	Origin and Pathogenesis of Pelvic (Ovarian, Tubal, and Primary Peritoneal) Serous Carcinoma. Annual Review of Pathology: Mechanisms of Disease, 2014, 9, 27-45.	9.6	142
62	HLA-G is a potential tumor marker in malignant ascites. Clinical Cancer Research, 2003, 9, 4460-4.	3.2	141
63	Papillary Tubal Hyperplasia. American Journal of Surgical Pathology, 2011, 35, 1605-1614.	2.1	140
64	The Development of High-grade Serous Carcinoma From Atypical Proliferative (Borderline) Serous Tumors and Low-grade Micropapillary Serous Carcinoma. American Journal of Surgical Pathology, 2007, 31, 1007-1012.	2.1	139
65	Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma. International Journal of Gynecological Pathology, 2016, 35, 48-55.	0.9	136
66	Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 14004-14009.	3.3	135
67	Molecular Pathogenesis of Ovarian Borderline Tumors: New Insights and Old Challenges. Clinical Cancer Research, 2005, 11, 7273-7279.	3.2	131
68	Shortened Telomeres in Serous Tubal Intraepithelial Carcinoma: An Early Event in Ovarian High-grade Serous Carcinogenesis. American Journal of Surgical Pathology, 2010, 34, 829-836.	2.1	127
69	Cystic and Adenofibromatous Clear Cell Carcinomas of the Ovary. American Journal of Surgical Pathology, 2009, 33, 844-853.	2.1	126
70	HLA-G Immunoreactivity Is Specific for Intermediate Trophoblast in Gestational Trophoblastic Disease and Can Serve as a Useful Marker in Differential Diagnosis. American Journal of Surgical Pathology, 2002, 26, 914-920.	2.1	125
71	IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. Modern Pathology, 2009, 22, 469-475.	2.9	125
72	Validation of an Algorithm for the Diagnosis of Serous Tubal Intraepithelial Carcinoma. International Journal of Gynecological Pathology, 2012, 31, 243-253.	0.9	125

#	Article	IF	Citations
73	Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules. Cancer Cell, 2015, 28, 82-96.	7.7	125
74	Amplicon profiles in ovarian serous carcinomas. International Journal of Cancer, 2007, 120, 2613-2617.	2.3	124
75	Ubiquitin-Proteasome System Stress Sensitizes Ovarian Cancer to Proteasome Inhibitorâ€“Induced Apoptosis. Cancer Research, 2006, 66, 3754-3763.	0.4	123
76	Characterization of Active Mitogen-Activated Protein Kinase in Ovarian Serous Carcinomas. Clinical Cancer Research, 2004, 10, 6432-6436.	3.2	121
77	A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 18739-18744.	3.3	121
78	Assessment of Plasma DNA Levels, Allelic Imbalance, and CA 125 as Diagnostic Tests for Cancer. Journal of the National Cancer Institute, 2002, 94, 1697-1703.	3.0	119
79	Placental site nodule and characterization of distinctive types of intermediate trophoblast. Human Pathology, 1999, 30, 687-694.	1.1	118
80	Mutational Analysis of K-ras Segregates Ovarian Serous Carcinomas into Two Types: Invasive MPSC (Low-grade Tumor) and Conventional Serous Carcinoma (High-grade Tumor). International Journal of Gynecological Pathology, 2003, 22, 37-41.	0.9	116
81	Amplification of 11q13 in ovarian carcinoma. Genes Chromosomes and Cancer, 2008, 47, 481-489.	1.5	116
82	Inactivation of the Mitogen-Activated Protein Kinase Pathway as a Potential Target-Based Therapy in Ovarian Serous Tumors with KRAS or BRAF Mutations. Cancer Research, 2005, 65, 1994-2000.	0.4	114
83	Jagged-1 and Notch3 Juxtacrine Loop Regulates Ovarian Tumor Growth and Adhesion. Cancer Research, 2008, 68, 5716-5723.	0.4	113
84	A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human highâ€grade serous carcinoma development. Journal of Pathology, 2014, 233, 228-237.	2.1	112
85	ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas. Modern Pathology, 2014, 27, 255-261.	2.9	110
86	PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8+ T-cell Function. Cancer Immunology Research, 2019, 7, 257-268.	1.6	108
87	Ovarian Cancer is an Imported Disease: Fact or Fiction?. Current Obstetrics and Gynecology Reports, 2012, 1, 1-9.	0.3	105
88	Roles of Deletion of Arid1a, a Tumor Suppressor, in Mouse Ovarian Tumorigenesis. Journal of the National Cancer Institute, 2014, 106, .	3.0	105
89	The Origin of Ovarian Cancer Species and Precancerous Landscape. American Journal of Pathology, 2021, 191, 26-39.	1.9	102
90	Gene Expression Signatures Differentiate Ovarian/Peritoneal Serous Carcinoma from Diffuse Malignant Peritoneal Mesothelioma. Clinical Cancer Research, 2006, 12, 5944-5950.	3.2	100

#	Article	IF	Citations
91	Clinicopathological Significance of Loss of ARID1A Immunoreactivity in Ovarian Clear Cell Carcinoma. International Journal of Molecular Sciences, 2010, 11, 5120-5128.	1.8	100
92	Pathogenesis and the Role of ARID1A Mutation in Endometriosis-related Ovarian Neoplasms. Advances in Anatomic Pathology, 2013, 20, 45-52.	2.4	98
93	Apolipoprotein E is required for cell proliferation and survival in ovarian cancer. Cancer Research, 2005, 65, 331-7.	0.4	97
94	HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma. Gynecologic Oncology, 2005, 96, 42-47.	0.6	90
95	Functional Analysis of In-frame Indel ARID1A Mutations Reveals New Regulatory Mechanisms of Its Tumor Suppressor Functions. Neoplasia, 2012, 14, 986-993.	2.3	89
96	Somatic Mutations of PPP2R1A in Ovarian and Uterine Carcinomas. American Journal of Pathology, 2011, 178, 1442-1447.	1.9	88
97	Loss of ARID1A Expression Correlates With Stages of Tumor Progression in Uterine Endometrioid Carcinoma. American Journal of Surgical Pathology, 2013, 37, 1342-1348.	2.1	88
98	Cyclin E and p16 Immunoreactivity in Epithelioid Trophoblastic Tumor???An Aid in Differential Diagnosis. American Journal of Surgical Pathology, 2006, 30, 1105-1110.	2.1	86
99	Human transposon insertion profiling: Analysis, visualization and identification of somatic LINE-1 insertions in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E733-E740.	3.3	86
100	Jagged1 Expression Regulated by Notch3 and Wnt/Î²-catenin Signaling Pathways in Ovarian Cancer. Oncotarget, 2010, 1, 210-218.	0.8	86
101	DNA Copy Numbers Profiles in Affinity-Purified Ovarian Clear Cell Carcinoma. Clinical Cancer Research, 2010, 16, 1997-2008.	3.2	85
102	Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthase. Modern Pathology, 2010, 23, 844-855.	2.9	84
103	Genomic landscape and evolutionary trajectories of ovarian cancer precursor lesions. Journal of Pathology, 2019, 248, 41-50.	2.1	84
104	Identifying tumor origin using a gene expression-based classification map. Cancer Research, 2003, 63, 4144-9.	0.4	84
105	Trophogram, an immunohistochemistry-based algorithmic approach, in the differential diagnosis of trophoblastic tumors and tumorlike lesions. Annals of Diagnostic Pathology, 2007, 11, 228-234.	0.6	82
106	Diffuse Mesothelin Expression Correlates with Prolonged Patient Survival in Ovarian Serous Carcinoma. Clinical Cancer Research, 2006, 12, 827-831.	3.2	81
107	Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy. Journal of Pathology, 2014, 232, 473-481.	2.1	81
108	Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 449, 31-39.	1.4	80

#	Article	IF	Citations
109	Immunohistochemistry of Choriocarcinoma. American Journal of Surgical Pathology, 2007, 31, 1726-1732.	2.1	80
110	GATA-3 Expression in Trophoblastic Tissues. American Journal of Surgical Pathology, 2015, 39, 101-108.	2.1	80
111	Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor Therapy. Clinical Cancer Research, 2019, 25, 5584-5594.	3.2	80
112	Oncoproteomic Analysis Reveals Co-Upregulation of RELA and STAT5 in Carboplatin Resistant Ovarian Carcinoma. PLoS ONE, 2010, 5, e11198.	1.1	79
113	Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer. Cell Reports, 2018, 22, 3393-3400.	2.9	77
114	Cancer Implications for Patients with Endometriosis. Seminars in Reproductive Medicine, 2017, 35, 110-116.	0.5	76
115	Defining the Cut Point Between Low-grade and High-grade Ovarian Serous Carcinomas. American Journal of Surgical Pathology, 2009, 33, 1220-1224.	2.1	75
116	Endocervical-type Mucinous Borderline Tumors are Related to Endometrioid Tumors Based on Mutation and Loss of Expression of ARID1A. International Journal of Gynecological Pathology, 2012, 31, 297-303.	0.9	74
117	Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?. Gynecologic Oncology, 2017, 147, 85-91.	0.6	74
118	Low-grade serous ovarian cancer: State of the science. Gynecologic Oncology, 2020, 156, 715-725.	0.6	74
119	Molecular Basis of Gestational Trophoblastic Diseases. Current Molecular Medicine, 2002, 2, 1-12.	0.6	73
120	CCNE1 amplification and centrosome number abnormality in serous tubal intraepithelial carcinoma: further evidence supporting its role as a precursor of ovarian high-grade serous carcinoma. Modern Pathology, 2016, 29, 1254-1261.	2.9	72
121	Functional Analysis of 11q13.5 Amplicon Identifies Rsf-1 (HBXAP) as a Gene Involved in Paclitaxel Resistance in Ovarian Cancer. Cancer Research, 2009, 69, 1407-1415.	0.4	70
122	Molecular Classification and Emerging Targeted Therapy in Endometrial Cancer. International Journal of Gynecological Pathology, 2020, 39, 26-35.	0.9	69
123	Ovarian Brenner tumour: A morphologic and immunohistochemical analysis suggesting an origin from fallopian tube epithelium. European Journal of Cancer, 2013, 49, 3839-3849.	1.3	68
124	Molecular Genetic Analysis of Placental Site Trophoblastic Tumors and Epithelioid Trophoblastic Tumors Confirms Their Trophoblastic Origin. American Journal of Pathology, 2002, 161, 1033-1037.	1.9	67
125	Identification of Pbx1, a Potential Oncogene, as a Notch3 Target Gene in Ovarian Cancer. Cancer Research, 2008, 68, 8852-8860.	0.4	66
126	Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions. Human Pathology, 2009, 40, 1453-1460.	1.1	66

#	Article	IF	Citations
127	NAC-1 Controls Cell Growth and Survival by Repressing Transcription of Gadd45GIP1, a Candidate Tumor Suppressor. Cancer Research, 2007, 67, 8058-8064.	0.4	64
128	Precursor Lesions of High-Grade Serous Ovarian Carcinoma: Morphological and Molecular Characteristics. Journal of Oncology, 2010, 2010, 1-9.	0.6	64
129	HLA-G and Immune Evasion in Cancer Cells. Journal of the Formosan Medical Association, 2010, 109, 248-257.	0.8	64
130	Notch3 Interactome Analysis Identified WWP2 as a Negative Regulator of Notch3 Signaling in Ovarian Cancer. PLoS Genetics, 2014, 10, e1004751.	1.5	64
131	Gene expression signatures of primary and metastatic uterine leiomyosarcoma. Human Pathology, 2014, 45, 691-700.	1.1	63
132	Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer. Gynecologic Oncology, 2021, 163, 246-253.	0.6	62
133	Ovarian Cancer Chemoresistance Relies on the Stem Cell Reprogramming Factor PBX1. Cancer Research, 2016, 76, 6351-6361.	0.4	61
134	UNDO: a Bioconductor R package for unsupervised deconvolution of mixed gene expressions in tumor samples. Bioinformatics, 2015, 31, 137-139.	1.8	60
135	Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma. Human Pathology, 2012, 43, 2197-2206.	1.1	59
136	HSD3B1 as a Novel Trophoblast-associated Marker That Assists in the Differential Diagnosis of Trophoblastic Tumors and Tumorlike Lesions. American Journal of Surgical Pathology, 2008, 32, 236-242.	2.1	57
137	Expression of Fatty Acid Synthase Depends on NAC1 and Is Associated with Recurrent Ovarian Serous Carcinomas. Journal of Oncology, 2010, 2010, 1-12.	0.6	57
138	Rsf-1, a Chromatin Remodeling Protein, Induces DNA Damage and Promotes Genomic Instability. Journal of Biological Chemistry, 2010, 285, 38260-38269.	1.6	57
139	Defining NOTCH3 Target Genes in Ovarian Cancer. Cancer Research, 2012, 72, 2294-2303.	0.4	57
140	Frequent CCNE1 amplification in endometrial intraepithelial carcinoma and uterine serous carcinoma. Modern Pathology, 2014, 27, 1014-1019.	2.9	54
141	Molecular genetic analysis of ovarian serous cystadenomas. Laboratory Investigation, 2004, 84, 778-784.	1.7	53
142	The Roles of Human Sucrose Nonfermenting Protein 2 Homologue in the Tumor-Promoting Functions of Rsf-1. Cancer Research, 2008, 68, 4050-4057.	0.4	53
143	The roles of ARID1A in gynecologic cancer. Journal of Gynecologic Oncology, 2013, 24, 376.	1.0	53
144	Independent development of endometrial epithelium and stroma within the same endometriosis. Journal of Pathology, 2018, 245, 265-269.	2.1	53

#	Article	IF	Citations
145	Amplification of the ch19p13.2 NACC1 locus in ovarian high-grade serous carcinoma. Modern Pathology, 2011, 24, 638-645.	2.9	52
146	Mutational analysis of <scp>BRAF</scp> and <scp>KRAS</scp> in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants. Journal of Pathology, 2014, 232, 16-22.	2.1	52
147	Prognostic and therapeutic impact of the chromosome 20q13.2 ZNF217 locus amplification in ovarian clear cell carcinoma. Cancer, 2012, 118, 2846-2857.	2.0	51
148	Ki-67 Labeling Index as an Adjunct in the Diagnosis of Serous Tubal Intraepithelial Carcinoma. International Journal of Gynecological Pathology, 2012, 31, 416-422.	0.9	50
149	BRAF Mutation Is Associated With a Specific Cell Type With Features Suggestive of Senescence in Ovarian Serous Borderline (Atypical Proliferative) Tumors. American Journal of Surgical Pathology, 2014, 38, 1603-1611.	2.1	50
150	Assessing aneuploidy with repetitive element sequencing. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 4858-4863.	3.3	50
151	Pathogenesis of ovarian cancer: clues from selected overexpressed genes. Future Oncology, 2009, 5, 1641-1657.	1.1	49
152	Homozygous deletion of MKK4 in ovarian serous carcinoma. Cancer Biology and Therapy, 2006, 5, 630-634.	1.5	48
153	The Diagnostic and Biological Implications of Laminin Expression in Serous Tubal Intraepithelial Carcinoma. American Journal of Surgical Pathology, 2012, 36, 1826-1834.	2.1	48
154	Clonality analysis of combined Brenner and mucinous tumours of the ovary reveals their monoclonal origin. Journal of Pathology, 2015, 237, 146-151.	2.1	48
155	Mevalonate Pathway Antagonist Suppresses Formation of Serous Tubal Intraepithelial Carcinoma and Ovarian Carcinoma in Mouse Models. Clinical Cancer Research, 2015, 21, 4652-4662.	3.2	48
156	CCNE1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis. Modern Pathology, 2017, 30, 297-303.	2.9	48
157	Fallopian Tube Lesions in Women at High Risk for Ovarian Cancer: A Multicenter Study. Cancer Prevention Research, 2018, 11, 697-706.	0.7	47
158	Clinical and biological significance of HLA-G expression in ovarian cancer. Seminars in Cancer Biology, 2007, 17, 436-443.	4.3	46
159	Characterization of the Immune Cell Repertoire in the Normal Fallopian Tube. International Journal of Gynecological Pathology, 2014, 33, 581-591.	0.9	46
160	Ovarian cancer specific kallikrein profile in effusions. Gynecologic Oncology, 2007, 105, 501-507.	0.6	45
161	Inactivating ARID1A Tumor Suppressor Enhances TERT Transcription and Maintains Telomere Length in Cancer Cells. Journal of Biological Chemistry, 2016, 291, 9690-9699.	1.6	45
162	Inactivation of Arid1a in the endometrium is associated with endometrioid tumorigenesis through transcriptional reprogramming. Nature Communications, 2020, 11, 2717.	5.8	45

#	Article	IF	Citations
163	Overexpression of a Chromatin Remodeling Factor, RSF-1/HBXAP, Correlates with Aggressive Oral Squamous Cell Carcinoma. American Journal of Pathology, 2011, 178, 2407-2415.	1.9	44
164	Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers. Cancer Research, 2020, 80, 4514-4526.	0.4	44
165	MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells. Diagnostic Cytopathology, 2007, 35, 756-760.	0.5	43
166	Distinct DNA methylation profiles in ovarian serous neoplasms and their implications in ovarian carcinogenesis. American Journal of Obstetrics and Gynecology, 2010, 203, 584.e1-584.e22.	0.7	43
167	HLA-G Upregulation in Pre-Malignant and Malignant Lesions of the Gastrointestinal Tract. International Journal of Gastrointestinal Cancer, 2005, 35, 015-024.	0.4	42
168	The Role of E-cadherin in the Motility and Invasion of Implantation Site Intermediate Trophoblast. Placenta, 2002, 23, 706-15.	0.7	42
169	The pathogenesis of atypical proliferative Brenner tumor: an immunohistochemical and molecular genetic analysis. Modern Pathology, 2014, 27, 231-237.	2.9	41
170	Uterine serous carcinoma: key advances and novel treatment approaches. International Journal of Gynecological Cancer, 2021, 31, 1165-1174.	1.2	40
171	Identification of PBX1 Target Genes in Cancer Cells by Global Mapping of PBX1 Binding Sites. PLoS ONE, 2012, 7, e36054.	1.1	40
172	Methylomic Analysis of Ovarian Cancers Identifies Tumor-Specific Alterations Readily Detectable in Early Precursor Lesions. Clinical Cancer Research, 2018, 24, 6536-6547.	3.2	39
173	Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. Cancer, 2019, 125, 1963-1972.	2.0	39
174	Genomic characterization of genes encoding histone acetylation modulator proteins identifies therapeutic targets for cancer treatment. Nature Communications, 2019, 10, 733.	5.8	39
175	Molecular Genetic Analysis of Appendiceal Mucinous Adenomas in Identical Twins, Including One With Pseudomyxoma Peritonei. American Journal of Surgical Pathology, 2001, 25, 1095-1099.	2.1	38
176	Expression of Rsf-1, a chromatin-remodeling gene, in ovarian and breast carcinoma. Human Pathology, 2006, 37, 1169-1175.	1.1	38
177	Increased proliferation in atypical hyperplasia/endometrioid intraepithelial neoplasia of the endometrium with concurrent inactivation of ARID1A and PTEN tumour suppressors. Journal of Pathology: Clinical Research, 2015, 1, 186-193.	1.3	38
178	Assessing tumors in living animals through measurement of urinary Î²-human chorionic gonadotropin. Nature Medicine, 2000, 6, 711-714.	15.2	37
179	Apply innovative technologies to explore cancer genome. Current Opinion in Oncology, 2005, 17, 33-38.	1.1	37
180	Laminin C1 expression by uterine carcinoma cells is associated with tumor progression. Gynecologic Oncology, 2015, 139, 338-344.	0.6	37

#	Article	IF	Citations
181	Loss of ARID1A expression in endometrial samplings is associated with the risk of endometrial carcinoma. Gynecologic Oncology, 2018, 150, 426-431.	0.6	36
182	Long Interspersed Nuclear Element 1 Retrotransposons Become Deregulated during the Development of Ovarian Cancer Precursor Lesions. American Journal of Pathology, 2019, 189, 513-520.	1.9	35
183	Expression Patterns of VEGF and Flk-1 in Human Endometrium during the Menstrual Cycle. Journal of Reproduction and Infertility, 2015, 16, 3-9.	1.0	35
184	Precursors of ovarian cancer in the fallopian tube: <scp>S</scp>erous tubal intraepithelial carcinoma â€“ an update. Journal of Obstetrics and Gynaecology Research, 2015, 41, 6-11.	0.6	34
185	Epigenomic Reprogramming toward Mesenchymal-Epithelial Transition in Ovarian-Cancer-Associated Mesenchymal Stem Cells Drives Metastasis. Cell Reports, 2020, 33, 108473.	2.9	34
186	RSF1 Is a Positive Regulator of NF-ÎºBâ€“Induced Gene Expression Required for Ovarian Cancer Chemoresistance. Cancer Research, 2014, 74, 2258-2269.	0.4	33
187	Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma. American Journal of Surgical Pathology, 2019, 43, 1462-1472.	2.1	33
188	Rsfâ€1, a chromatin remodelling protein, interacts with cyclin <scp>E1</scp> and promotes tumour development. Journal of Pathology, 2013, 229, 559-568.	2.1	32
189	Nuclear size distinguishes low- from high-grade ovarian serous carcinoma and predicts outcome. Human Pathology, 2005, 36, 1049-1054.	1.1	30
190	Expression and clinical role of the bric-a-brac tramtrack broad complex/poxvirus and zinc protein NAC-1 in ovarian carcinoma effusions. Human Pathology, 2007, 38, 1030-1036.	1.1	30
191	Diagnostic potential of tumor DNA from ovarian cyst fluid. ELife, 2016, 5, .	2.8	30
192	Telomere length in different histologic types of ovarian carcinoma with emphasis on clear cell carcinoma. Modern Pathology, 2011, 24, 1139-1145.	2.9	29
193	The Role of Forkhead Box Q1 Transcription Factor in Ovarian Epithelial Carcinomas. International Journal of Molecular Sciences, 2012, 13, 13881-13893.	1.8	29
194	NAC1 Is an Actin-Binding Protein That Is Essential for Effective Cytokinesis in Cancer Cells. Cancer Research, 2012, 72, 4085-4096.	0.4	29
195	Mutant BRAF Induces DNA Strand Breaks, Activates DNA Damage Response Pathway, and Up-Regulates Glucose Transporter-1 in Nontransformed Epithelial Cells. American Journal of Pathology, 2012, 180, 1179-1188.	1.9	29
196	T cell-inflamed phenotype and increased Foxp3 expression in infiltrating T-cells of mismatch-repair deficient endometrial cancers. Modern Pathology, 2019, 32, 576-584.	2.9	29
197	Application of Human Leukocyte Antigenâ€“G Expression in the Diagnosis of Human Cancer. Human Immunology, 2007, 68, 272-276.	1.2	28
198	Activation of Mitogen-Activated Protein Kinase Is Required for Migration and Invasion of Placental Site Trophoblastic Tumor. American Journal of Pathology, 2005, 167, 879-885.	1.9	27

#	Article	IF	Citations
199	Dysfunction of Nucleus Accumbens-1 Activates Cellular Senescence and Inhibits Tumor Cell Proliferation and Oncogenesis. Cancer Research, 2012, 72, 4262-4275.	0.4	27
200	Adenocarcinoma of Mullerian origin: review of pathogenesis, molecular biology, and emerging treatment paradigms. Gynecologic Oncology Research and Practice, 2015, 2, 1.	3.6	27
201	Genomeâ€wide mutation analysis in precancerous lesions of endometrial carcinoma. Journal of Pathology, 2021, 253, 119-128.	2.1	27
202	Endometriosis: benign, malignant, or something in between?. Oncotarget, 2017, 8, 78263-78264.	0.8	27
203	The novel ZIP4 regulation and its role in ovarian cancer. Oncotarget, 2017, 8, 90090-90107.	0.8	27
204	Pathology and Pathogenesis of Adenomyosis. Seminars in Reproductive Medicine, 2020, 38, 108-118.	0.5	25
205	ARID1A immunohistochemistry improves outcome prediction in invasive urothelial carcinoma of urinary bladder. Human Pathology, 2014, 45, 2233-2239.	1.1	24
206	Cell cycle-dependent alteration in NAC1 nuclear body dynamics and morphology. Physical Biology, 2011, 8, 015005.	0.8	23
207	TET1 reprograms the epithelial ovarian cancer epigenome and reveals casein kinase 2Î± as a therapeutic target. Journal of Pathology, 2019, 248, 363-376.	2.1	23
208	Trophoblastic vasculogenic mimicry in gestational choriocarcinoma. Modern Pathology, 2011, 24, 646-652.	2.9	22
209	Inhibition of ovarian tumor cell invasiveness by targeting SYK in the tyrosine kinase signaling pathway. Oncogene, 2018, 37, 3778-3789.	2.6	22
210	Current and Emerging Methods for Ovarian Cancer Screening and Diagnostics: A Comprehensive Review. Cancers, 2022, 14, 2885.	1.7	22
211	Measurement of Cyclin E Genomic Copy Number and Strand Length in Cell-Free DNA Distinguish Malignant versus Benign Effusions. Clinical Cancer Research, 2007, 13, 5805-5809.	3.2	21
212	Rsf-1 (HBXAP) Expression is Associated With Advanced Stage and Lymph Node Metastasis in Ovarian Clear Cell Carcinoma. International Journal of Gynecological Pathology, 2011, 30, 30-35.	0.9	21
213	Identification of the NAC1-Regulated Genes in Ovarian Cancer. American Journal of Pathology, 2014, 184, 133-140.	1.9	21
214	Metastatic Epithelioid Trophoblastic Tumor in a Male Patient With Mixed Germ-cell Tumor of the Testis. American Journal of Surgical Pathology, 2009, 33, 1902-1905.	2.1	20
215	High level of chromosomal aberration in ovarian cancer genome correlates with poor clinical outcome. Gynecologic Oncology, 2013, 128, 500-505.	0.6	20
216	Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma. Human Pathology, 2017, 68, 87-91.	1.1	19

#	Article	IF	Citations
217	Proteome-wide Tyrosine Phosphorylation Analysis Reveals Dysregulated Signaling Pathways in Ovarian Tumors. Molecular and Cellular Proteomics, 2019, 18, 448-460.	2.5	19
218	Loss of NAC1 Expression Is Associated with Defective Bony Patterning in the Murine Vertebral Axis. PLoS ONE, 2013, 8, e69099.	1.1	19
219	Bokhman's dualistic model of endometrial carcinoma. Revisited. Gynecologic Oncology, 2013, 129, 271-272.	0.6	18
220	Tubal origin of ovarian cancerÂâ€“Âthe doubleâ€edged sword of haemoglobin. Journal of Pathology, 2017, 242, 3-6.	2.1	18
221	Oncogenic BRAF and KRAS mutations in endosalpingiosis. Journal of Pathology, 2020, 250, 148-158.	2.1	18
222	KDDN: an open-source Cytoscape app for constructing differential dependency networks with significant rewiring. Bioinformatics, 2015, 31, 287-289.	1.8	17
223	Molecular analysis of ovarian mucinous carcinoma reveals different cell of origins. Oncotarget, 2015, 6, 22949-22958.	0.8	17
224	DNA Damage Response is Prominent in Ovarian High-Grade Serous Carcinomas, Especially Those with Rsf-1 (HBXAP) Overexpression. Journal of Oncology, 2012, 2012, 1-7.	0.6	16
225	Loss of ALDH1A1 expression is an early event in the pathogenesis of ovarian high-grade serous carcinoma. Modern Pathology, 2015, 28, 437-445.	2.9	16
226	Evolution of a Trophoblastic Tumor From an Endometrioid Carcinomaâ€”A Morphological and Molecular Analysis. International Journal of Gynecological Pathology, 2011, 30, 117-120.	0.9	15
227	ChIP-BIT: Bayesian inference of target genes using a novel joint probabilistic model of ChIP-seq profiles. Nucleic Acids Research, 2016, 44, e65-e65.	6.5	15
228	Analysis of Telomere Lengths in p53 Signatures and Incidental Serous Tubal Intraepithelial Carcinomas Without Concurrent Ovarian Cancer. American Journal of Surgical Pathology, 2019, 43, 1083-1091.	2.1	15
229	Urothelial Carcinomas With Trophoblastic Differentiation, Including Choriocarcinoma. American Journal of Surgical Pathology, 2020, 44, 1322-1330.	2.1	15
230	Methylomic Landscapes of Ovarian Cancer Precursor Lesions. Clinical Cancer Research, 2020, 26, 6310-6320.	3.2	15
231	Placental Site Trophoblastic Tumorâ€”Past as Prologue. Gynecologic Oncology, 2001, 82, 413-414.	0.6	14
232	Profiling the activity of G proteins in patient-derived tissues by rapid affinity-capture of signal transduction proteins (GRASP). Proteomics, 2004, 4, 812-818.	1.3	14
233	Dedifferentiated endometrioid adenocarcinoma: An under-recognized but aggressive tumor?. Gynecologic Oncology Case Reports, 2013, 5, 25-27.	0.9	14
234	Epithelial Cells in Endometriosis and Adenomyosis Upregulate STING Expression. Reproductive Sciences, 2020, 27, 1276-1284.	1.1	14

#	Article	IF	Citations
235	Lack of a Y-Chromosomal Complement in the Majority of Gestational Trophoblastic Neoplasms. Journal of Oncology, 2010, 2010, 1-6.	0.6	13
236	Mutation of PPP2R1A: a new clue in unveiling the pathogenesis of uterine serous carcinoma. Journal of Pathology, 2011, 224, 1-4.	2.1	13
237	Gestational Trophoblastic Tumors and Related Tumor-Like Lesions. , 2011, , 1075-1135.		13
238	Identification and characterization of membralin, a novel tumor-associated gene, in ovarian carcinoma. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2005, 1730, 96-102.	2.4	12
239	Power of the Eternal Youth. American Journal of Pathology, 2008, 173, 911-914.	1.9	12
240	Elucidating the pathogenesis of synchronous and metachronous tumors in a woman with endometrioid carcinomas using a whole-exome sequencing approach. Journal of Physical Education and Sports Management, 2017, 3, a001693.	0.5	12
241	Development of small molecule inhibitors targeting PBX1 transcription signaling as a novel cancer therapeutic strategy. IScience, 2021, 24, 103297.	1.9	12
242	Osteopontin expression in ovarian carcinoma effusions is related to improved clinical outcome. Human Pathology, 2011, 42, 991-997.	1.1	11
243	Expression of the chromatin remodeling factor Rsf-1 is down-regulated in breast carcinoma effusions. Human Pathology, 2008, 39, 616-622.	1.1	10
244	Immunohistochemical expression of ARID1A in penile squamous cell carcinomas: a tissue microarray study of 112 cases. Human Pathology, 2015, 46, 761-766.	1.1	10
245	CINdex: A Bioconductor Package for Analysis of Chromosome Instability in DNA Copy Number Data. Cancer Informatics, 2017, 16, 1176935117746663.	0.9	10
246	Epithelial Tumors of the Ovary. , 2019, , 841-966.		10
247	BRAFV600E-mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma. Oncotarget, 2019, 10, 6870-6878.	0.8	10
248	Precancerous Lesions of Ovarian Cancerâ€"A US Perspective. Journal of the National Cancer Institute, 2018, 110, 692-693.	3.0	9
249	Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer. EBioMedicine, 2019, 47, 184-194.	2.7	9
250	Sub-millimeter endoscope demonstrates feasibility of in vivo reflectance imaging, fluorescence imaging, and cell collection in the fallopian tubes. Journal of Biomedical Optics, 2021, 26, .	1.4	9
251	A novel human endometrial epithelial cell line for modeling gynecological diseases and for drug screening. Laboratory Investigation, 2021, 101, 1505-1512.	1.7	9
252	Mutation and methylation profiles of ectopic and eutopic endometrial tissues. Journal of Pathology, 2021, 255, 387-398.	2.1	8

#	Article	IF	Citations
253	Dendritic cells transduced with Rsf-1/HBXAP gene generate specific cytotoxic T lymphocytes against ovarian cancer in vitro. Biochemical and Biophysical Research Communications, 2010, 394, 633-638.	1.0	7
254	Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence. Cancer Prevention Research, 2016, 9, 713-720.	0.7	7
255	BACOM2.0 facilitates absolute normalization and quantification of somatic copy number alterations in heterogeneous tumor. Scientific Reports, 2015, 5, 13955.	1.6	6
256	NAC1 attenuates BCL6 negative autoregulation and functions as a BCL6 coactivator of FOXQ1 transcription in cancer cells. Aging, 2020, 12, 9275-9291.	1.4	6
257	Biomarker Identification by Knowledge-Driven Multi-Level ICA and Motif Analysis. , 2007, , .		5
258	Advances in the diagnosis of gestational trophoblastic tumors and tumor-like lesions. Expert Opinion on Medical Diagnostics, 2009, 3, 371-380.	1.6	5
259	Reply to Haffner et al.: DNA hypomethylation renders tumors more immunogenic. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E8583-E8584.	3.3	5
260	Gestational Trophoblastic Lesions. , 2009, , 645-665.		4
261	Pathogenesis of Gestational Trophoblastic Lesions. , 2007, , 157-166.		3
262	Detecting aberrant signal transduction pathways from high-throughput data using GIST algorithm. , 2012, , .		2
263	Gestational Trophoblastic Tumors and Related Tumorlike Lesions. , 2019, , 1307-1375.		2
264	Not All Peritoneal Implants Are Created Equal. Gynecologic Oncology, 2020, 156, 1-2.	0.6	2
265	Progestin and aromatase inhibitor therapy in recurrent, estrogen/progestin receptor positive uterine carcinosarcoma: A case report. Gynecologic Oncology Reports, 2021, 38, 100877.	0.3	2
266	Pathogenesis and New Therapeutic Targets of Ovarian Cancer. Journal of Oncology, 2012, 2012, 1-2.	0.6	1
267	Screening for Ovarian Cancer: A Reality Check. Current Obstetrics and Gynecology Reports, 2013, 2, 73-75.	0.3	1
268	Genomic and network analysis to study the origin of ovarian cancer. Systems Biomedicine (Austin, Tex) Tj ETQq0 0 0 rgBT /Overlock 10 T	0.7	1
269	Expression of Cell Competition Markers at the Interface between p53 Signature and Normal Epithelium in the Human Fallopian Tube. PLoS ONE, 2016, 11, e0156069.	1.1	1
270	Biologically inspired survival analysis based on integrating gene expression as mediator with genomic variants. Computers in Biology and Medicine, 2016, 77, 231-239.	3.9	1

#	Article	IF	Citations
271	Gestational Trophoblastic Tumors and Related Tumorlike Lesions. , 2018, , 1-71.		1
272	Cytomorphologic and molecular analyses of fallopian tube fimbrial brushings for diagnosis of serous tubal intraepithelial carcinoma. Cancer Cytopathology, 2019, 127, 192-201.	1.4	1
273	Follicular fluid has more to offer: Insulin-like growth factor axis on ovarian carcinogenesis. EBioMedicine, 2019, 41, 30-31.	2.7	1
274	Molecular Pathology of Ovarian Cancer. , 2013, , 129-149.		1
275	Analyzing DNA Copy Number Changes Using Fused Margin Regression. , 2009, , .		0
276	Accurate Estimation of Genomic Deletions and Normal Cell Contamination by Bayesian Analysis of Mixtures. , 2009, , .		0
277	Accurate identification of significant aberrations in contaminated cancer genome. , 2012, , .		0
278	Epithelial Tumors of the Ovary. , 2018, , 1-128.		0
279	Gestational Trophoblastic Lesions. , 2020, , 871-903.		0
280	Epithelial Tumors of the Ovary. , 2018, , 1-128.		0